Specialist Psychiatry & Psychotherapy, and Neurology
Andrei leads our medical direction with quiet confidence and a sharp eye for what truly matters in clinical care. As Chief Medical Officer, he ensures that our medical standards are not only high, but also human — grounded in evidence, guided by compassion, and designed to meet people where they are.
A board-certified physician in Psychiatry and Psychotherapy, Neurology, and Emergency Medicine, Andrei brings together an unusually broad perspective. He’s a member of the Swiss Society of Addiction Medicine (SSAM) and holds an MBA, but what stands out most is how he puts his knowledge into practice: clear-sighted, practical, and always open to innovation.
Andrei doesn’t fit the stereotype of a psychiatrist. He’s approachable, curious, and deeply collaborative — qualities that have helped shape NEOVIVA’s modern, inclusive approach to treatment. Clients and colleagues alike value his ability to listen carefully, ask the right questions, and find thoughtful, workable solutions.
When he’s not guiding our clinical direction, you might find him out on the lake, paddle in hand, letting the quiet do its work.
Academic career
2018 – Specialist in Psychiatry and Psychotherapy, Bavarian State Medical Association, Germany
2015 – Specialist (FA) in Neurology, Bavarian State Medical Association, Germany
2010 – Doctorate (Dr. med.), Technical University Dresden, Germany
Professional career
Since May 2022: Chief Physician and Member of the Executive Board, NEOVIVA, Vitznau
Since February 2020: Chief Physician and Member of the Executive Board, ANCO Healthcare, Zug
Mar 2020 – Mar 2022: Senior Physician, Deputy Medical Director, Klinik Meissenberg AG, Switzerland
Jan 2019 – Feb 2020: Attending Physician, Crisis Management Department, License to Practice in the Canton of Zug, Klinik Meissenberg AG, Switzerland
May 2017 – Oct 2018: Senior Resident with Personnel Responsibility, Head of the Closed Ward for Addiction Medicine, Clinic and Polyclinic for Psychiatry and Psychotherapy, University of Regensburg, Germany
Selected Publications
- Wirth AM, Johannesen S, Khomenko A, Baldaranov D, Bruun TH, Wendl C, Schuierer G, Greenlee MW, Bogdahn U. Value of fluid-attenuated inversion recovery MRI data analyzed by the lesion segmentation toolbox in amyotrophic lateral sclerosis Journal of Magnetic Resonance Imaging JMRI. 2019 Aug;50(2):552-559. doi: 10.1002/jmri.26577. Epub 2018 Dec 19. PMID: 30569457; PMCID: PMC6767504.
- Wirth AM, Khomenko A, Baldaranov D, Kobor I, Hsam O, Grimm T, Johannesen S, Bruun TH, Schulte-Mattler W, Greenlee MW, Bogdahn U. Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of Individual Patients With Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis. Front Neurol. 2018 Jul 30;9:614. doi: 10.3389/fneur.2018.00614. PMID: 30104996; PMCID: PMC6077217
- Baldaranov, Khomenko A, Kobor I, Bogdahn U, Gorges M, Kassubek J, Müller HP. Longitudinal Diffusion Tensor Imaging-Based Assessment of Tract Alterations: An Application to Amyotrophic Lateral Sclerosis. Front Hum Neurosci. 2017 Dec 5;11:567. doi: 10.3389/fnhum.2017.00567. PMID: 29259550; PMCID: PMC5723297.
- Kirzinger L, Khomenko A, Schulte-Mattler W, Backhaus R, Platen S, Schalke B. Myopathy in Childhood Muscle-Specific Kinase Myasthenia Gravis. Pediatric Neurology 2016 Dec;65:90-92.
- Grassinger J, Khomenko A, Hart C, Baldaranov D, Johannesen SW, Mueller G, Schelker R, Schulte-Mattler W, Andreesen R, Bogdahn U. Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis. Cytokine 2014 May;67(1):21-8